Genmab A/S
NASDAQ:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
NASDAQ:GMAB
Watchlist
Price: 33.15 USD 0.67%
Market Cap: $21B

Operating Margin

36.8%
Current
Improving
by 1.5%
vs 3-y average of 35.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
36.8%
=
Operating Income
kr1.3B
/
Revenue
kr3.6B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
36.8%
=
Operating Income
$1.3B
/
Revenue
kr3.6B

Peer Comparison

Country Company Market Cap Operating
Margin
DK
Genmab A/S
CSE:GMAB
127.8B DKK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Higher than 90% of companies in Denmark
Percentile
90th
Based on 506 companies
90th percentile
36.8%
Low
-5 981.6% — 1.3%
Typical Range
1.3% — 16.3%
High
16.3% — 423.3%
Distribution Statistics
Denmark
Min -5 981.6%
30th Percentile 1.3%
Median 7.5%
70th Percentile 16.3%
Max 423.3%

Genmab A/S
Glance View

In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.

GMAB Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
36.8%
=
Operating Income
kr1.3B
/
Revenue
kr3.6B
What is Genmab A/S's current Operating Margin?

The current Operating Margin for Genmab A/S is 36.8%, which is above its 3-year median of 35.3%.

How has Operating Margin changed over time?

Over the last 3 years, Genmab A/S’s Operating Margin has increased from 36.8% to 36.8%. During this period, it reached a low of 31.6% on Jun 30, 2024 and a high of 43.5% on Dec 31, 2022.

Back to Top